Cowen Prime Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Cowen Prime Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-2,000	Closed	-$8K	–	247
2015 Q2	$8K	Sell	2,000 -41,025	-95%	-$164K	﹤0.01%	214
2015 Q1	$186K	Hold	43,025	–	–	0.08%	117
2014 Q4	$128K	Hold	43,025	–	–	0.05%	142
2014 Q3	$143K	Sell	43,025 -1,925	-4%	-$5.03K	0.06%	129
2014 Q2	$114K	Buy	44,950 +1,400	+3%	+$2.99K	0.04%	126
2014 Q1	$98K	Buy	43,550 +13,550	+45%	+$28.3K	0.04%	139
2013 Q4	$59K	Buy	+30,000	New	+$60.6K	0.02%	168

Other funds holding CPRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Cowen Prime Advisors's CPRX Position: Q3 2015 in Review

Cowen Prime Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q3 2015, closing a stake of 2,000 shares — an estimated $8K sold.

Cowen Prime Advisors first reported a position in CPRX in Q4 2013 and held it in 7 quarters. The position peaked at $186K in Q1 2015. 90 funds tracked by Wall St. Rank hold CPRX as of Q3 2015.

Cowen Prime Advisors reported no remaining Catalyst Pharmaceutical position as of Q3 2015 after selling out during the quarter.
Cowen Prime Advisors sold 2,000 Catalyst Pharmaceutical shares in Q3 2015, an estimated $8K.
Cowen Prime Advisors first reported a position in Catalyst Pharmaceutical in Q4 2013 and held it in 7 quarters.
Cowen Prime Advisors's Catalyst Pharmaceutical position peaked at $186K in Q1 2015.
90 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2015.

Based on Cowen Prime Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.